Type 2 diabetes: what it is, causes, symptoms, diagnosis, and treatment overview
Type 2 diabetes is a common metabolic disease in which blood glucose stays too high because the body does not use insulin well enough and, over time, often cannot make enough insulin. It usually develops in adults, though it is rising in younger people with obesity. Care combines lifestyle, medicines, and monitoring — goals are individualized, and remission is possible for some, not a guaranteed cure.
What is type 2 diabetes?
Type 2 diabetes means plasma glucose is chronically elevated. Insulin from the pancreas normally helps muscle, fat, and liver take up glucose after meals. In type 2 diabetes:
- Insulin resistance — tissues respond poorly to insulin, so more insulin is needed.
- Beta-cell strain — over years, insulin-producing cells often fatigue; production may become inadequate.
Together, these raise fasting and post-meal glucose. The shift from normal → prediabetes → diabetes is usually gradual and can take years. Many people have no clear symptoms until screening or a complication prompts testing.
How it differs from other diabetes types
| Type | Core idea |
|---|---|
| Type 1 diabetes | Autoimmune loss of beta cells; insulin is required from diagnosis |
| Type 2 diabetes | Insulin resistance + progressive insulin deficiency; lifestyle and oral/injectable drugs often first |
| Gestational diabetes | Diabetes first recognized in pregnancy; raises later type 2 risk |
| Other forms | Secondary diabetes, MODY, pancreatogenic diabetes — less common |
Labels such as “adult-onset” or “childhood” diabetes are outdated: type 1 can start at any age, and type 2 now appears in adolescents in high-obesity settings.
Causes and risk factors
Obesity and energy balance
Overweight and obesity — especially excess abdominal (visceral) fat — are the strongest modifiable risk factors. Rising calorie density and less daily movement over recent decades track the global rise in type 2 diabetes far better than gene change alone. See also the obesity hub.
BMI (weight in kg ÷ height in m²) is a screening tool, not a full health verdict. WHO categories run from normal weight (18.5–24.9) through overweight (25–29.9) to obesity classes (≥ 30). Some ethnic groups (for example many people of South Asian ancestry) develop type 2 at lower BMI; screening thresholds may be lower in those groups per local guidelines.
Genes and family history
Having a parent or sibling with type 2 diabetes raises risk. Dozens of gene variants (including TCF7L2) are associated with modest risk increases. Shared habits and environments matter too: families often share diet, activity, and body-weight patterns. For most people, environment and lifestyle outweigh any single gene.
Age, ethnicity, and other factors
- Risk rises with age as beta-cell capacity declines.
- Non-European ancestry groups often present earlier and at lower BMI.
- Prior gestational diabetes strongly predicts later type 2.
- Smoking is independently associated with higher risk.
- Low-grade inflammation, sleep disruption, certain medicines (e.g. long-term glucocorticoids), and gut–hormone signaling (incretins such as GLP-1) are active research areas that already inform modern drugs.
Honest prevention framing: large prevention studies show that healthy weight, diet quality, and physical activity can prevent or delay many type 2 cases. Exact percentages vary by population and study; lifestyle is powerful but not a guarantee for every individual.
Symptoms
Symptoms are often subtle. Common features:
- Thirst and frequent urination
- Fatigue and increased hunger
- Blurred vision that may fluctuate with glucose
- Slow-healing wounds or recurrent infections
- Dark, velvety skin folds (acanthosis nigricans)
- Unexplained weight loss in more advanced insulin deficiency
A dedicated overview of common and less familiar signs is on diabetes symptoms. Symptoms do not replace blood tests.
At diagnosis, a substantial minority already have early eye, kidney, nerve, or heart disease — another reason screening matters.
Diagnosis
Diagnosis uses standardized glucose and/or HbA1c criteria. Thresholds below follow common European / Manualen-style plasma glucose cutoffs; ADA uses similar glucose numbers (mg/dL) and HbA1c ≥ 6.5% for diagnosis in most adults. Confirm with a clinician — laboratory method and local protocol matter.
| Venous plasma | Capillary | |
|---|---|---|
| Diabetes — fasting | ≥ 7.0 mmol/L (≥ 126 mg/dL) | ≥ 7.0 mmol/L |
| Diabetes — 2 h after 75 g OGTT | ≥ 11.1 mmol/L (≥ 200 mg/dL) | ≥ 12.2 mmol/L |
| Prediabetes / IFG — fasting | 6.1–6.9 mmol/L (often cited in Europe) | same band |
| Impaired glucose tolerance — 2 h OGTT | 7.8–11.0 mmol/L (venous) | 8.9–12.1 mmol/L (capillary) |
Also used:
- Random glucose ≥ 11.1 mmol/L (≥ 200 mg/dL) with classic symptoms
- HbA1c ≥ 48 mmol/mol (6.5%) — see HbA1c normal values and cutoffs
Usually two abnormal results are required unless the clinical picture is clear. HbA1c can be unreliable in some anemias, hemoglobinopathies, pregnancy, or advanced kidney disease.
Diagnostic cutoffs are not treatment targets. Once diabetes is diagnosed, goals are individualized (age, hypoglycemia risk, comorbidities).
Who should be screened?
Many guidelines suggest glucose/HbA1c screening in adults with overweight/obesity plus risk factors, and from midlife even without symptoms — earlier in high-risk ethnic groups or after gestational diabetes. Roughly one in three people with type 2 diabetes worldwide may be undiagnosed at any time; local figures vary.
Treatment overview
There is no single “best” plan for everyone. Modern care (ADA/EASD-style) layers:
- Lifestyle foundation — food pattern, activity, sleep, smoking cessation, weight management
- Medicines chosen for glucose and heart/kidney benefit when indicated
- Cardiorenal risk reduction — blood pressure, lipids, antiplatelet therapy when appropriate
- Education and monitoring — HbA1c, home glucose or CGM when useful
Do not start, stop, or change prescription drugs from this page alone.
Medicines (high-level map)
| Class / approach | Role (simplified) | Future EN link |
|---|---|---|
| Metformin | Common first-line; low hypoglycemia risk | /en/treatments/metformin-side-effects/ |
| SGLT2 inhibitors | Glucose lowering + kidney/heart benefit in selected patients | /en/sglt2-inhibitors/ |
| GLP-1 receptor agonists | Glucose, weight, and CV benefit in selected patients | /en/glp-1/ |
| Other orals (DPP-4, sulfonylureas, etc.) | Individualized; hypoglycemia risk varies | /en/treatments/ |
| Insulin | Often needed as beta-cell capacity falls, or earlier if glucose is very high | /en/treatments/ |
Drug choice depends on HbA1c, heart failure, chronic kidney disease, atherosclerotic disease, weight, cost, and preferences. Details belong on dedicated treatment pages after medical review.
Metabolic surgery
Bariatric / metabolic surgery can produce large, sustained improvements and remission (normal glucose without diabetes medicines for a defined period) in carefully selected people with obesity and type 2 diabetes. It is a major intervention with risks, lifelong nutritional follow-up, and eligibility criteria — not a casual alternative to tablets. Remission after surgery or intensive lifestyle is not the same as a permanent guaranteed “cure”; relapse can occur.
Lifestyle: food, activity, weight
Eating patterns
No single diet suits every culture or preference. Patterns with the strongest support for cardiometabolic health include Mediterranean-style eating, other whole-food patterns with controlled energy intake, and — for some people under clinical guidance — lower-carbohydrate approaches. Priorities that usually help:
- Overall energy balance if weight loss is a goal
- Plenty of vegetables, fiber, and minimally processed foods
- Limiting sugar-sweetened drinks and ultra-processed snacks
- Sustainable habits over short extremes
See upcoming EN diet/lifestyle siblings under this hub as they are drafted.
Physical activity
Regular movement improves insulin sensitivity and cardiovascular fitness. Both aerobic activity and resistance training help; even reducing long sitting bouts matters. Start at a safe level if you have complications (feet, heart, eyes) — ask your care team.
Weight and remission
Meaningful weight loss can lower glucose dramatically, especially early after diagnosis. Some people achieve remission with intensive diet programs (as discussed in clinical literature such as McCombie et al., BMJ). Remission means glucose returns to the non-diabetes range without glucose-lowering drugs for a period — not “cured forever.” Maintenance and follow-up remain essential.
Complications and monitoring
Long-term high glucose damages small vessels (microvascular: retina, kidney, nerves) and contributes to macrovascular disease (heart attack, stroke, peripheral artery disease), alongside blood pressure, lipids, smoking, and kidney function.
Protective habits:
- Regular HbA1c and clinic follow-up
- Blood pressure and cholesterol management
- Eye screening, foot checks, kidney labs (eGFR, albuminuria)
- Vaccinations and infection awareness
- Sick-day rules; know when ketones matter (uncommon in type 2, still possible)
Hubs for deeper reading: cardiovascular disease and diabetes, diabetic kidney disease, diabetes complications, hypoglycemia.
Living with type 2 diabetes — practical outlook
Type 2 diabetes is serious and common, but outcomes vary widely. People who keep multiple risk factors in range often have substantially lower event rates than those with many out-of-range factors — Swedish registry research has quantified this pattern (Rawshani et al., N Engl J Med 2018). Knowledge, realistic goals, and a durable care relationship matter more than perfection on any single day.
If you are newly diagnosed: learn symptoms and HbA1c, agree a monitoring plan, and ask which medicines and lifestyle steps fit your heart, kidney, and hypoglycemia profile.
Related English hubs (planned)
- /en/diabetes/ — general diabetes overview
- /en/diabetes/hba1c/ — normal values, diagnosis vs targets
- /en/diabetes/symptoms/ — common and less familiar signs
- /en/type-1-diabetes/
- /en/diabetes/prediabetes/
- /en/treatments/ · /en/glp-1/ · /en/sglt2-inhibitors/
- /en/obesity/ · /en/cardiovascular-disease/diabetes/
Sources
- Live Swedish pair: diabetes.nu type 2 diabetes overview (Araz Rawshani et al.; clinical educational content)
- Diabetes Manualen / Diabeteshandboken — diagnostic tables and care orientation (diabetes.nu)
- ADA Standards of Care in Diabetes — diagnosis, screening, individualized glycemic and cardiorenal care
- EASD / ADA Consensus Report on the management of hyperglycemia in type 2 diabetes
- NICE NG28 — type 2 diabetes in adults (UK; general principles where cited internationally)
- McCombie L et al. Beating type 2 diabetes into remission. BMJ 2017 (remission framing — not “cure”)
- Rawshani A, Rawshani A, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2018;379:633–644